Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 9c; Offers FY23 EPS Guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $246.81 -0.31%
EPS Growth %: -20.5%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -20.5%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.84, $0.09 worse than the analyst estimate of $4.93. Revenue for the quarter came in at $972 million versus the consensus estimate of $969.02 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2023 EPS of $18.15-$19.00, versus the consensus of $18.66.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
